Clinical Trial

Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Study acronym: LA-ESCC
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 21, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
A prospective trial design was used to evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1/PD-L1 inhibitors in the treatment of locally advanced resectable esophageal squamous cell carcinoma.
Trial Details
NCT Number NCT06888531
Lead Sponsor Henan Cancer Hospital
Collaborators: Zhengzhou University
Conditions Esophageal Malignant Neoplasm Primary
Enrollment 30 participants
Start Date 2025-03-08
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-21